FEG
UTHR icon

Financial Enhancement Group’s United Therapeutics UTHR Stock Holding History

Financial Enhancement Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,616
Closed -$3.95M – 149
2024
Q3 		$3.95M Buy
+18,616
New +$6.29M 0.77% 42
2023
Q2 		– Sell
-18,616
Closed -$3.95M – 132
2023
Q1 		$3.95M Buy
18,616
+1,567
+9% +$386K 0.77% 42
2022
Q4 		$4.31M Buy
17,049
+279
+2% +$70.4K 0.83% 46
2022
Q3 		$3.51M Buy
16,770
+244
+1% +$54.5K 0.81% 31
2022
Q2 		$3.89M Buy
+16,526
New +$3.36M 0.84% 31

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Financial Enhancement Group's UTHR Position: Q4 2024 in Review

Financial Enhancement Group sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 18,616 shares — an estimated $3.95M sold.

Financial Enhancement Group first reported a position in UTHR in Q2 2022 and held it in 5 quarters. The position peaked at $4.31M in Q4 2022. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

  • Financial Enhancement Group reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Financial Enhancement Group sold 18,616 United Therapeutics shares in Q4 2024, an estimated $3.95M.
  • Financial Enhancement Group first reported a position in United Therapeutics in Q2 2022 and held it in 5 quarters.
  • Financial Enhancement Group's United Therapeutics position peaked at $4.31M in Q4 2022.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on Financial Enhancement Group's 13F filing for Q4 2024, filed 14 Jan 2025.